Fubotv earnings beat by $0.10, revenue topped estimates
Igm Biosciences (NASDAQ:IGMS) Chief Executive Officer Mary Beth Harler sold 14,501 shares of common stock on July 23, 2025, in a transaction valued at $18,456. The sale comes as the company’s stock has declined nearly 80% year-to-date, according to InvestingPro data.
The shares were sold at a weighted average price of $1.2728, with individual sales prices ranging from $1.27 to $1.275. Following the transaction, Harler directly owns 323,680 shares of Igm Biosciences, which currently has a market capitalization of approximately $76 million.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. With the company’s next earnings report due in 16 days, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports.
In other recent news, IGM Biosciences announced a definitive merger agreement to be acquired by Concentra Biosciences. Under the terms of this agreement, Concentra will purchase IGM Biosciences for $1.247 in cash per share, along with a non-tradeable contingent value right (CVR). This CVR allows shareholders to receive 100% of IGM’s closing net cash exceeding $82 million and 80% of any net proceeds from the sale of certain product candidates and intellectual property within a year of the merger’s closing. Additionally, IGM Biosciences recently terminated a major collaboration and license agreement with Genzyme Corporation, a Sanofi (NASDAQ:SNY) entity. The agreement, initially set to develop and commercialize IgM antibodies for diseases like cancer, was mutually discontinued as both parties decided it was not in their best interests to continue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.